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Abstract
Background: Telomere erosion can lead to genomic instability and cancer progression. It has been suggested that
the shortest telomere, not the average telomere length (TL), is critical for cell viability. Some studies have shown
shorter TL in myelodysplastic syndrome (MDS) patients but the critically short telomeres, the variability of TL within
individual patient has not been evaluated. Thus, we aimed to investigate the TL of MDS patients and assessed the
association of TL with recurrent genetic mutations in MDS.
Methods: We measured the TL of bone marrow nucleated cells for diagnostic samples at a single-cell level by
quantitative fluorescence in situ hybridization (Q-FISH) for 58 MDS patients and analyzed the minimum, median,
average, standard deviation, average of the 0th to 10th percentile TL within a patient, and the proportion of cells
with TL that is shorter than the lowest 10th percentile of the normal control (NC). The correlations of TL to clinical
parameters, cytogenetic results, and genetic mutations were assessed.
Results: MDS patients showed eroded telomeres and narrow distribution compared to the NC (P < 0.001, P = 0.018,
respectively). Patients with mutation showed significantly lesser cells with short TL, below the lowest 10th percentile of
the NC (P = 0.017), but no differences in TL were found according to mutations/cytogenetic abnormalities except for
CSF3R mutation. However, those patients with a high percentage (≥80 %) of cells with short TL showed poorer overall
survival (P = 0.021), and this was an independent prognostic factor, along with TP53, U2AF1 mutation, and high BM
blast count (P = 0.044, 0.001, 0.004, 0.012, respectively).
Conclusions: The shortest TL, which determines the fate of the cell, was significantly shorter, and higher burden of
cells with short TL were found in MDS, which correlated with poor survival, suggesting the need to measure TL in
single cells by Q-FISH.
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Background
Telomeres are non-coding, repetitive sequences of DNA
at the ends of the chromosomes of eukaryotic cells which
become shorter as cells divide, and when telomere attri-
tion reaches its limit, cell proliferation arrest, senescence,
and apoptosis can occur [1, 2]. Shortened telomeres can
cause end-to-end fusion of chromosomes, which results in
genomic instability and contributes to carcinogenesis [3].
Thus, telomeres and their maintenance have been studied
in many hematologic malignancies [4–6].
Myelodysplastic syndromes (MDS) are clonal
hematopoietic stem cell diseases characterized by cytope-
nia, dysplasia, and ineffective hematopoiesis, with an in-
creased risk of transformation to acute myeloid leukemia
(AML) [7, 8]. Due to its predisposition to AML, genomic
instability has been studied as the key to the pathogenesis
of MDS, and thus, many studies have assessed the telo-
mere components of MDS [9–11]. MDS patients have
shown a shorter average telomere length (TL) compared
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to normal control (NC), but the association of TL to other
clinical parameters in patients with MDS has been incon-
sistent [9, 11, 12].
Many somatic mutations have been identified in patients
with MDS, involving various pathways including epigenetic
regulation, RNA splicing machinery, and transcription fac-
tors [13–15], which help elucidate the pathophysiology of
the disease. A recent study showed that telomere dysfunc-
tion causes aberrant RNA splicing by repressing the spli-
cing gene expression [16]. However, the correlation of TL
with various genetic mutations other than telomerase com-
plex genes has not been thoroughly explored [17, 18].
Moreover, most previous studies have used Southern
blot analysis, quantitative PCR, or flow fluorescence in situ
hybridization (FISH) for the analysis of TL [9, 11, 19, 20].
However, these studies only assessed the mean or median
TL of the patient whereas it is believed that the cell with
the shortest telomere is actually the critical factor leading
telomere dysfunction [3, 21]. Performing quantitative-FISH
(Q-FISH) for telomeres allows the measurement of TL at a
single-cell level with the measurement of the distribution
of TL of within individuals as well as the shortest TL [22].
Telomeres of individual chromosomes are stained with
peptic nucleic acid probes for telomeres, and the fluores-
cence intensity of the telomeric signal is measured with
fluorescence-based automatic microscope [23]. The fluor-
escence intensity is normalized by the use of an additional
centromeric probe, and the telomere to centromere (T/C)
fluorescence intensity ratio is considered to be the surro-
gate of TL since the fluorescence intensity of the telomeric
signal is known to be proportional to the TL [24]. Inclusion
of the centromeric probe also allows the selection of single
cells in which two centromeric signals are observed and
the normalization of the signal for hybridization [23].
Performing Q-FISH in interphase nuclei further allows
measurement of each value in numerous nucleated cells.
Therefore, we measured the TL of bone marrow (BM)
nucleated cells of patients with MDS at diagnosis by
Q-FISH, evaluated the correlation of the TL with genetic
mutations and clinical parameters, and explored the use-
fulness of TL parameters as a prognostic marker.
Methods
Patients
This study examined 58 patients diagnosed with MDS
(37 men and 21 women) at Seoul National University
Hospital between January 2004 and December 2014. This
study was approved by the institutional review board of
Seoul National University Hospital (1604-082-754). The
samples included in this study were from diagnostic
samples of MDS. The characteristics of the MDS patients
are shown in Table 1. BM aspirates from 23 individuals
who underwent marrow biopsy and showed no evidence
of hematologic malignancy were included as the NC. The
bone marrow of the NC showed no evidence of bone mar-
row involvement and showed normal karyotype.
Karyotyping—Giemsa banding
A standard protocol was used to perform Giemsa banding
with heparinized whole blood marrow samples [25]. A
minimum of 20 metaphase cells were karyotyped according
to the International System for Human Cytogenetic
Nomenclature (ISCN) [26, 27].
Interphase fluorescence in situ hybridization for MDS
Interphase FISH tests (del(5q)/−5, del(7q)/−7, trisomy 8,
del(20q), trisomy 1/1q+) were performed. The probes
used were Vysis LSI EGR1 (5q31)/D5S23, D5S721 Dual
color probe kit, Vysis LSI D7S522 (7q31)/CEP7 FISH
probe, Vysis CEP8(Dz82) Spectrum Green Probe, Vysis
D20S108 FISH probe, and Vysis LSI 1p36/LSI1q25 and
LSI 19q13/19p13 Dual color probe (Abbott Molecular,
Downers Grove, IL, USA). These five types of FISH items
were selected based on the previous report of recurrent
cytogenetic changes in Korean patients with MDS [28].
FISH was performed with mononuclear cells of BM
aspirates at the time of BM examination as described in
a previous study [28].
Telomere quantitative fluorescence in situ hybridization
Cryopreserved BM nucleated cells in fixative after FISH
preparation were used for telomere analysis. Q-FISH was
performed using a Cy3-labelled telomere PNA (peptide
nucleic acid) FISH kit (DakoCytomation Denmark A/S,
Glostrup, Denmark) and a FITC-labeled PNA probe for
the centromere of chromosome 2 (kindly provided by
DakoCytomation). One microliter of the probe for the
centromere of chromosome 2 was added to 10 μL of the
telomere probe. Telomere and centromere Q-FISH hybrid-
izations were performed according to the manufacturer’s
instructions. Interphase Q-FISH images were captured
with a Zeiss Axioplan 2 imaging microscope (Carl Zeiss
MicroImaging GmbH, Munchen, Germany) equipped
with ISIS software (MetaSystems GmbH, Altlussheim,
Germany) (Fig. 1). For TL measurements, the ISIS-
Telomere module (MetaSystems) was used as described
previously [23]. The software calculates a T/C fluorescence
intensity ratio, which is a measure of TL, for individual
cells. At least 25 interphase nuclei were scanned for each
patient to measure the TL. The cell with the shortest TL is
represented as the minimum TL and the lower 25th
percentile value of each individual is expressed as the
“Q1” TL. The median, the average and the distribution
of TL, standard distribution (SD), and the average of
the 0th to 10th percentile TL for each individual was
calculated from the total cells of which the TL was
measured. Furthermore, the percentage of cells with TL
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shorter than the 10th percentile of the normal control
was assessed and stated as “short” TL.
Targeted sequencing
Eighty-seven genes were selected for targeted sequencing
(Additional file 1: Table S1). Genes that were previously
reported as mutational targets in MDS (n = 49) [13, 14, 29]
or those mutated in other myeloid and lymphoid
hematologic malignancies (n = 11 and n = 27) were in-
cluded [13, 14, 29–35]. The BM aspirates collected in a
sodium ethylenediaminetetraacetic acid tube were treated
with ammonium chloride for RBC lysis, and the cell pel-
lets were kept in RNAlater solution (Qiagen, Valencia,
CA, USA) at −80 °C until genetic analysis. The genomic
DNA (gDNA) was extracted from the buffy coat of BM
aspirate using QIAamp DNA Blood Mini Kit (Qiagen),
according to the manufacturer’s instructions. The gDNA
shearing, standard library production, and hybridization
were performed by Celemics Inc. (Seoul, Korea). The
quality of the gDNA was assessed by the Agilent 2200
Table 1 Characteristics of MDS patients (n = 58)
Characteristics Number (%)
Gender (Male/female) 37: 21




Complete blood count at bone marrow sample collection
White blood cell (103/μL) 2.6 (0.6–17.2)
Hemoglobin (g/dL) 8.0 (4.4–12.2)
Absolute neutrophil count (/μL) 1151 (80–11,345)
Platelet count (103/μL) 74.5 (3–1029)

















Very High 12 (20.7)
Cytogenetic results
Karyotype
Abnormal karyotype 32 (55.2)
Complex karyotype (>3 abnormalities) 9 (15.5)
del(5q)/ –5 6 (10.5)
del(7q)/ –7 8 (14.0)
Trisomy 8 8 (14.0)
Abnormal 17p 3 (5.2)
del(20q) 5 (8.8)
Fluorescence in situ hybridization
Abnormal chromosome 1a 5 (11.1)
Abnormal chromosome 5b 8 (17.4)
Table 1 Characteristics of MDS patients (n = 58) (Continued)
Abnormal chromosome 7b 9 (19.6)
Abnormal chromosome 8b 7 (15.2)
Abnormal chromosome 20b 4 (8.7)
RCUD refractory cytopenia of unilineage dysplasia, RCMD refractory cytopenia
of multilineage dysplasia, MDS, U myelodysplastic syndrome, unclassifiable,
IPSS International Prognostic Scoring System
aOnly performed in 45 patients
bPerformed in 46 patients
Fig. 1 Interphase telomere fluorescence in situ hybridization (FISH)
image. FISH results obtained with pan-telomere (cyanine (Cy)3-labeled)
and centromere 2 specific (fluorescein isothiocyanate (FITC)-labeled)
peptic nucleic acid probe in interphase nuclei. Counter stain was
performed with 4′,6-diamidino-2-phenylindole (DAPI) to identify
the nuclei
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TapeStation System (Agilent, Santa Clara, CA, USA). A
total target length of the 259-kb region using the paired-
end 150-bp rapid-run sequencing mode was performed
on an Illumina Hiseq 2500 platform (Illumina, San Diego,
CA, USA). The sequencing data calling process is de-
scribed in Additional file 1.
Statistical analysis
Categorization of MDS patients was performed according
to the 2008 World Health Organization (WHO) classifica-
tion of tumors of hematopoietic and lymphoid tissues [8],
the International Prognostic Scoring System (IPSS), and
the revised IPSS et al. [36, 37]. The correlation of TL with
various clinical parameters, BM findings, cytogenetic ab-
normalities, and mutations found in multi-gene panels
was assessed.
The gene mutations were evaluated separately and in
subgroups according to the function of genes. Ten gene
subgroups are splicing machinery, DNA methylation, chro-
matin modification, transcription factor, receptor/kinases,
RAS pathway, cell signaling, DNA repair/cell cycle, co-
hesion, and miscellaneous. The genes in each subgroup
are listed in the Additional file 1: Table S1. The χ2 test
and Fisher’s exact test were used to compare categorical
variables. Pairwise correlations between TLs and gene
mutations, cytogenetic results, and categorical clinical
parameters were evaluated using Kendall tau-b (Tb)
correlation. For linear parameters, Pearson’s r correlation
was used. The comparisons of TLs between patients with
and without a certain mutation were made with the
Mann-Whitney method for genes that showed mutation
in more than 5.0 % of the patients.
The overall survival (OS) was calculated from the date
of diagnosis to the date of death from any cause and
compared by Kaplan-Meier method (log-rank test). Uni-
variable and multivariable Cox analyses were performed
to assess variables as prognostic factors for survival.
Backward LR selection was performed for multivariable
Cox analysis. Harrell’s C-index was calculated for the
proposed multivariable Cox model and the revised IPSS.
Statistical analyses were performed using the SPSS ver-
sion 22.0 (IBM Inc., Chicago, IL, USA) and R statistical
program (http://www.r-project.org). P values <0.05 were
considered to be statistically significant.
Results
Telomere lengths and clinical profiles
We compared the telomere lengths (TLs) of the MDS
patients (n = 58) with those of the NC (n = 23), according
to several parameters (Table 2). The clinical characteristics
of the MDS patients included in this study are shown in
Table 1. There was no significant difference in age and sex
(P = 0.175, 0.796, respectively) between the MDS patients
and NC. However, the number of cells assessed in the
MDS patients was smaller (P = 0.004) than that assessed
in the NC due to insufficient nuclei in the patient samples.
All of the TL parameters were significantly lower in the
MDS patients than the NC (P < 0.001 for all the TL except
SD, P = 0.018 for SD). The distribution of the telomere
length of each individual was narrower in the MDS pa-
tients than the NC (P = 0.018).
We also calculated the lowest 10th percentile TL value
of the NC group and found out that 52.1 (±24.9)% of
MDS patients’ cells were under this length (Table 2).
These results show that not only the mean TL of the
MDS patients is shorter than that of the NC but also a
large proportion of MDS patients’ cells are shorter than
the lowest 10th percentile TL of the NC.
TL was compared for WHO categories and IPSS risk
groups. The TL parameters were not different among the
clinical subgroups (the average of the 0th–10th percentile
TL and the median TL shown in Fig. 2, the other TL
Table 2 Telomere length parameters of MDS patients and normal control
Parameters Average ± SD P
valueMDS (n = 58) NC (n = 23)
Age 63.7 ± 14.6 60.9 ± 9.5 0.175
Gender (M/F) 37:21 16:7 0.796
No. of cells assessed for telomere lengths 77.6 ± 38.9 98.1 ± 26.3 0.004
Telomere lengths (T/C ratio)
Minimum 1.97 ± 1.47 4.41 ± 1.36 <0.001
25th percentile (Q1) 5.49 ± 3.04 11.79 ± 3.06 <0.001
Median 8.56 ± 4.45 15.92 ± 3.93 <0.001
Average 10.08 ± 4.73 17.29 ± 4.42 <0.001
Average of 0–10 percentile 2.95 ± 1.76 6.64 ± 1.74 <0.001
Standard Deviation 6.67 ± 3.01 8.07 ± 2.73 0.018
Cells under the 10th percentile of the NC (%) 52.1 ± 24.9
MDS myelodysplastic syndrome, NC normal control
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parameters are in the Additional file 1: Table S2).
Additional comparison of TL was made according to
the complete blood count and BM findings. Patients
with low hemoglobin (<8 g/dL) showed a higher per-
centage of cells with TL less than the 10th percentile
of normal control (P = 0.020). However, the other TL
parameters were not significantly different in those
patients with hemoglobin values less than vs. equal to/
greater than 8 g/dL. There were no significant differ-
ences in the TL according to absolute neutrophil
count, platelet count, BM blast count, fibrosis, or cel-
lularity (Additional file 1: Table S3).
Multi-gene panel results
Among the 87 genes, we found mutations of 43 genes in
more than one patient. Forty-five patients (77.6 %) had
showed mutation in one or more of the genes. Only the
gene mutations found in more than 5 % of the samples
are shown in Fig. 3. Grouping the 87 genes by gene
function, genes related to splicing were most frequently
mutated (34.5 %), following the genes for transcription
factors (31.0 %), chromatin modification (25.9 %), DNA
methylation (19.0 %), receptor/kinases (15.5 %), and RAS
pathways (8.6 %). The associations of gene mutations
and/or cytogenetic results are shown in Fig. 4. Kendall
tau-b (Tb) correlation coefficients greater than 0.40 were
present between SRSF2 and SETBP1 mutation (Tb =
0.432, P = 0.001), IDH2 and SRSF2 mutation (Tb = 0.432,
P = 0.001), TP53 mutation and del(5q)/−5 (Tb = 0.520,
P < 0.001), TP53 mutation and del(7q)/−7 (Tb = 0.564, P <
0.001), TP53 mutation and abnormalities of 17p (Tb = 0.583,
P < 0.001), del(5q)/−5 and abnormality of 17p (Tb = 0.431,
P = 0.001). Significant correlations were also present be-
tween DNMT3A vs. IDH2 mutation, DNMT3A vs.
SETBP1 mutation (Tb = 0.390, P = 0.003, respectively),
U2AF1 mutation vs. trisomy 8 (Tb = 0.379, P = 0.005),
del(7q)/−7 vs. abnormal 17p (Tb = 0.357, P = 0.008),
SF3B1 vs. TET2 mutation (Tb = 0.343, P = 0.010), DNMT3A
vs. TET2 mutation (Tb = 0.263, P = 0.047), IDH2 vs. RUNX1
mutation, RUNX1 vs. SETBP1 mutation, IDH2 vs. SETBP1
mutation (Tb = 0.297, P = 0.025, respectively). Comparing
the association between gene categories and cytogenetic ab-
normalities; DNA methylation vs. cell signaling-related
genes (Tb = 0.391, P = 0.003), DNA methylation vs. DNA
Fig. 2 Telomere lengths according to the World Health Organization (WHO) categories, International Prognostic Scoring System (IPSS), and revised
IPSS subgroups. T/C telomere to centromere
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repair/cell cycle-related genes (Tb = 0.389, P = 0.003), RAS
pathway vs. splicing-related genes (Tb = 0.294, P = 0.026),
splicing-related genes vs. trisomy 8 (Tb = 0.338, P = 0.011),
transcription factor genes vs. del(5q)/−5 (Tb = 0.276, P =
0.039), transcription factor genes vs. del(7q)/−7 (Tb = 0.399,
P = 0.003), transcription factor genes vs. abnormality of 17p
(Tb = 0.362, P = 0.007) were shown to have significant cor-
relations (Additional file 1: Figure S1).
Telomere length and genetic mutations/cytogenetic
abnormalities
We analyzed whether somatic mutations had a relation-
ship with TL. Table 3 shows the TL of patients according
to whether or not they have a certain somatic mutation.
Patients without gene mutations had shorter TL than
those with mutation. All of the TL parameters showed
significant differences (minimum, Q1, median, average,
average of 0–10 percentile, SD, percentage of cells under
the 10th percentile of the NC) between those patients
with or without gene mutations (P = 0.043, 0.041, 0.025,
0.014, 0.030, 0.007, 0.017, respectively). Looking at specific
mutations, the difference in TL was only present for those
with or without CSF3R mutation. Patients without CSF3R
mutation (n = 55) had a significantly higher percentage of
cells whose length was below the lowest 10th percentile
of the NC than those with CSF3R mutation (n = 3) (P =
0.037). In addition, comparisons were made for the TL
according to gene groups. However, there were no
Fig. 4 Correlations between gene mutations and cytogenetic changes. Significant correlations are marked with bold border
Fig. 3 The percentage of samples that was found with specific gene mutations in genes with mutations in more than 5 % of the patients
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Number Mean age P
value
Telomere lengths (T/C ratio)













Mut(+) 45 65.4 ± 12.2 0.356 2.14 ± 1.53 0.043 5.82 ± 3.07 0.041 8.99 ± 4.17 0.025 10.68 ± 4.56 0.014 3.18 ± 1.82 0.030 7.12 ± 2.97 0.007 48.2 ± 23.6 0.017
Mut(−) 13 57.9 ± 20.6 1.38 ± 1.11 4.34 ± 2.80 7.12 ± 5.26 8.00 ± 4.90 2.14 ± 1.32 5.13 ± 2.74 65.8 ± 25.5
ASXL1 Mut(+) 13 65.4 ± 10.8 0.837 2.13 ± 2.29 0.461 5.32 ± 3.79 0.557 8.04 ± 4.83 0.595 9.39 ± 5.20 0.450 2.97 ± 2.28 0.689 5.78 ± 2.40 0.310 57.4 ± 24.4 0.396
Mut(−) 45 63.2 ± 15.7 1.92 ± 1.17 5.54 ± 2.85 8.72 ± 4.39 10.28 ± 4.63 2.94 ± 1.62 6.93 ± 3.15 50.6 ± 25.1
CSF3R Mut(+) 3 57.3 ± 21.1 0.438 2.21 ± 0.99 0.438 7.87 ± 2.87 0.087 12.43 ± 3.71 0.062 14.23 ± 4.18 0.067 3.82 ± 2.29 0.459 9.23 ± 2.43 0.119 23.9 ± 13.8 0.037
Mut(−) 55 64.0 ± 14.4 1.96 ± 1.50 5.36 ± 3.03 8.36 ± 4.42 9.86 ± 4.69 2.90 ± 1.74 6.53 ± 3.00 53.7 ± 24.5
DNMT3A Mut(+) 7 72.0 ± 8.9 0.117 1.66 ± 0.77 1.000 4.38 ± 1.25 0.439 6.77 ± 1.58 0.425 8.14 ± 1.66 0.453 2.50 ± 0.75 0.907 5.43 ± 1.88 0.779 55.6 ± 15.4 0.312
Mut(−) 51 62.6 ± 15.0 2.01 ± 1.55 5.65 ± 3.20 8.82 ± 4.67 10.35 ± 4.96 3.01 ± 1.86 6.84 ± 3.12 51.7 ± 26.0
EZH2 Mut(+) 3 71.7 ± 0.6 0.240 3.95 ± 3.95 0.379 7.71 ± 5.74 0.547 10.66 ± 6.28 0.525 12.57 ± 7.71 0.502 4.44 ± 3.43 0.342 7.13 ± 3.97 0.869 62.3 ± 12.5 0.594
Mut(−) 55 63.3 ± 14.9 1.86 ± 1.22 5.37 ± 2.88 8.45 ± 4.39 9.95 ± 4.59 2.87 ± 1.65 6.65 ± 3.00 51.6 ± 25.4
IDH2 Mut(+) 3 66.7 ± 9.1 0.843 3.08 ± 2.20 0.232 6.18 ± 4.53 0.974 10.04 ± 6.42 0.715 11.70 ± 5.50 0.570 3.91 ± 2.73 0.525 8.05 ± 0.99 0.232 38.7 ± 29.1 0.525
Mut(−) 55 63.5 ± 14.9 1.91 ± 1.43 5.46 ± 3.00 8.49 ± 4.39 9.99 ± 4.73 2.90 ± 1.72 6.60 ± 3.08 52.9 ± 24.8
NOTCH1 Mut(+) 4 64.0 ± 17.1 0.824 2.47 ± 0.84 0.189 8.01 ± 4.97 0.348 11.94 ± 7.12 0.363 14.43 ± 7.72 0.236 4.24 ± 2.29 0.248 9.48 ± 3.33 0.067 35.3 ± 31.7 0.332
Mut(−) 54 63.7 ± 14.6 1.93 ± 1.51 5.31 ± 2.84 8.32 ± 4.19 9.76 ± 4.38 2.85 ± 1.71 6.46 ± 2.92 53.4 ± 24.2
PLEKHG5 Mut(+) 3 58.7 ± 10.3 0.324 1.01 ± 0.52 0.158 2.86 ± 2.05 0.111 5.07 ± 2.45 0.138 6.99 ± 3.37 0.291 1.57 ± 1.17 0.119 5.95 ± 2.90 0.843 70.3 ± 18.0 0.193
Mut(−) 55 64.0 ± 14.9 2.02 ± 1.49 5.64 ± 3.04 8.76 ± 4.47 10.25 ± 4.76 3.02 ± 1.77 6.71 ± 3.04 51.1 ± 25.0
RUNX1 Mut(+) 3 56.7 ± 10.6 0.193 2.13 ± 1.27 0.690 4.90 ± 1.76 0.843 10.16 ± 5.47 0.641 11.73 ± 5.44 0.570 2.83 ± 0.92 0.766 8.91 ± 4.08 0.193 58.0 ± 14.9 0.641
Mut(−) 55 64.1 ± 14.8 1.96 ± 1.49 5.53 ± 3.11 8.48 ± 4.44 9.99 ± 4.73 2.95 ± 1.80 6.55 ± 2.95 51.8 ± 25.4
SETBP1 Mut(+) 3 66.7 ± 20.0 0.895 1.76 ± 0.32 0.690 4.20 ± 1.02 0.547 6.48 ± 1.80 0.594 7.61 ± 2.03 0.459 2.41 ± 0.43 0.869 4.76 ± 2.01 0.246 58.6 ± 18.7 0.690
Mut(−) 55 63.5 ± 14.5 1.98 ± 1.51 5.56 ± 3.11 8.68 ± 4.54 10.22 ± 4.81 2.98 ± 1.81 6.78 ± 3.04 51.8 ± 25.3
SF3B1 Mut(+) 5 63.6 ± 11.2 0.788 2.09 ± 1.60 0.872 5.13 ± 1.68 0.747 7.99 ± 2.51 0.851 9.87 ± 3.23 0.768 2.72 ± 1.48 0.893 7.79 ± 3.99 0.553 47.2 ± 19.2 0.517
Mut(−) 53 63.7 ± 15.0 1.96 ± 1.48 5.53 ± 3.16 8.62 ± 4.61 10.10 ± 4.87 2.97 ± 1.80 6.57 ± 2.94 52.6 ± 25.5
SRSF2 Mut(+) 6 73.8 ± 8.0 0.101 2.40 ± 1.72 0.446 6.47 ± 3.76 0.558 10.10 ± 5.48 0.446 11.42 ± 5.68 0.508 3.70 ± 2.26 0.374 6.89 ± 2.55 0.737 42.4 ± 30.5 0.416
Mut(−) 52 62.5 ± 14.8 1.92 ± 1.45 5.38 ± 2.98 8.39 ± 4.35 9.93 ± 4.65 2.86 ± 1.70 6.65 ± 3.09 53.2 ± 24.3
TET2 Mut(+) 5 75.8 ± 6.1 0.021 2.85 ± 1.69 0.131 7.06 ± 2.70 0.086 10.06 ± 2.89 0.162 12.11 ± 3.22 0.138 3.91 ± 1.91 0.154 8.19 ± 3.81 0.316 33.4 ± 18.5 0.076
Mut(−) 53 62.6 ± 14.7 1.89 ± 1.44 5.35 ± 3.06 8.43 ± 4.57 9.89 ± 4.83 2.86 ± 1.74 6.53 ± 2.94 53.9 ± 24.8
TP53 Mut(+) 8 69.0 ± 8.9 0.471 1.81 ± 1.23 0.748 5.12 ± 3.06 0.974 8.44 ± 4.08 0.748 10.25 ± 4.36 0.650 2.67 ± 1.84 0.471 7.62 ± 3.05 0.260 47.2 ± 27.0 0.471

















Table 3 Telomere lengths according to gene mutations or cytogenetic changes (Continued)
U2AF1 Mut(+) 9 59.4 ± 12.7 0.179 2.02 ± 1.01 0.408 6.62 ± 3.49 0.225 10.39 ± 5.60 0.269 12.08 ± 6.35 0.318 3.49 ± 1.69 0.201 7.77 ± 4.21 0.512 47.6 ± 27.7 0.614
Mut(−) 49 64.5 ± 15.0 1.96 ± 1.55 5.29 ± 2.95 8.23 ± 4.20 9.71 ± 4.36 2.85 ± 1.78 6.47 ± 2.75 53.0 ± 24.6
Karyotype Normal 25 61.2 ± 15.1 0.416 2.00 ± 1.95 0.237 5.32 ± 3.44 0.385 7.95 ± 4.46 0.274 9.36 ± 4.93 0.222 2.93 ± 2.09 0.459 6.08 ± 3.01 0.216 57.7 ± 26.6 0.123
Abnormal 32 65.3 ± 14.3 1.92 ± 1.02 5.64 ± 2.80 9.00 ± 4.53 10.53 ± 4.61 2.94 ± 1.53 7.00 ± 2.96 48.3 ± 23.3
del(5q)/−5 (+) 6 68.7 ± 13.3 0.393 2.18 ± 1.20 0.500 6.71 ± 3.56 0.393 10.28 ± 4.58 0.233 12.33 ± 4.40 0.177 3.78 ± 2.16 0.352 8.39 ± 2.36 0.048 35.4 ± 28.4 0.089
(−) 51 62.9 ± 14.9 1.93 ± 1.52 5.35 ± 3.02 8.34 ± 4.48 9.75 ± 4.76 2.84 ± 1.73 6.39 ± 3.00 54.4 ± 24.1
del(7q)/−7 (+) 8 61.5 ± 18.6 0.866 2.13 ± 1.05 0.302 6.58 ± 3.00 0.111 10.44 ± 5.45 0.175 11.59 ± 4.90 0.207 3.25 ± 1.51 0.261 7.06 ± 2.96 0.449 39.8 ± 24.2 0.096
(−) 49 63.8 ± 14.2 1.93 ± 1.55 5.32 ± 3.08 8.23 ± 4.30 9.76 ± 4.73 2.89 ± 1.83 6.52 ± 3.02 54.5 ± 24.80
Trisomy 8 (+) 8 54.4 ± 20.5 0.123 1.87 ± 1.02 0.778 6.35 ± 3.84 0.628 11.09 ± 6.69 0.261 12.35 ± 6.63 0.291 2.95 ± 1.64 0.813 8.29 ± 4.26 0.302 51.3 ± 27.8 0.919
(−) 49 65.0 ± 13.2 1.97 ± 1.56 5.36 ± 2.96 8.12 ± 3.97 9.64 ± 4.34 2.94 ± 1.82 6.32 ± 2.69 52.6 ± 24.8
Abn 17p (+) 3 72.3 ± 10.1 0.307 2.72 ± 1.47 0.324 6.05 ± 3.84 0.749 8.89 ± 5.48 0.906 10.34 ± 5.00 0.880 3.72 ± 2.24 0.599 6.25 ± 1.63 0.801 45.4 ± 33.9 0.623
(−) 54 63.0 ± 14.8 1.91 ± 1.49 5.47 ± 3.07 8.52 ± 4.49 10.00 ± 4.78 2.90 ± 1.77 6.62 ± 3.06 52.8 ± 24.8
del(20q) (+) 5 68.0 ± 10.7 0.632 2.16 ± 0.55 0.186 5.56 ± 1.41 0.519 8.13 ± 2.15 0.795 9.70 ± 2.27 0.712 3.13 ± 0.73 0.262 6.12 ± 1.28 0.880 44.4 ± 15.0 0.327
(−) 52 63.1 ± 15.0 1.94 ± 1.55 5.49 ± 3.20 8.58 ± 4.66 10.05 ± 4.94 2.92 ± 1.85 6.65 ± 3.11 53.2 ± 25.8
FISH 1 (+) 5 54.0 ± 25.2 0.428 1.61 ± 1.04 0.562 7.03 ± 4.89 0.586 11.77 ± 7.84 0.368 13.19 ± 7.37 0.349 2.92 ± 2.09 0.903 8.99 ± 3.72 0.128 40.4 ± 29.4 0.314
(−) 40 63.0 ± 13.9 1.89 ± 1.18 5.49 ± 3.20 8.28 ± 3.98 9.71 ± 4.24 2.86 ± 1.64 6.34 ± 2.72 51.9 ± 25.4
FISH 5 (+) 8 67.3 ± 9.8 0.485 1.80 ± 1.20 0.765 5.60 ± 3.63 0.921 9.17 ± 4.77 0.559 10.97 ± 4.87 0.450 2.92 ± 2.23 0.579 7.86 ± 2.91 0.123 43.4 ± 30.7 0.338
(−) 38 61.3 ± 16.2 1.85 ± 1.15 5.45 ± 2.86 8.55 ± 4.52 9.88 ± 4.64 2.87 ± 1.54 6.33 ± 2.87 52.1 ± 24.5
FISH 7 (+) 9 69.3 ± 7.0 0.160 1.94 ± 1.08 0.605 5.57 ± 2.66 0.478 8.54 ± 3.65 0.643 10.08 ± 4.10 0.723 2.92 ± 1.63 0.870 6.69 ± 2.74 0.786 44.4 ± 15.04 0.461
(−) 37 60.6 ± 16.4 1.82 ± 1.18 5.46 ± 3.06 8.68 ± 4.75 10.07 ± 4.83 2.87 ± 1.67 6.58 ± 2.98 53.2 ± 25.8
FISH 8 (+) 7 59.6 ± 15.5 0.490 1.90 ± 1.10 0.858 5.77 ± 3.74 1.000 9.70 ± 5.85 0.697 11.43 ± 6.59 0.697 3.01 ± 1.76 0.881 7.90 ± 4.44 0.549 55.6 ± 27.2 0.549
(−) 39 62.8 ± 15.5 1.83 ± 1.17 5.43 ± 2.86 8.47 ± 4.30 9.82 ± 4.29 2.85 ± 1.65 6.37 ± 2.55 49.7 ± 25.5
FISH 20 (+) 4 64.3 ± 7.6 0.985 2.37 ± 1.03 0.173 5.82 ± 1.49 0.417 8.38 ± 2.22 0.721 9.85 ± 2.20 0.721 3.35 ± 1.06 0.229 6.02 ± 1.08 0.895 44.0 ± 15.3 0.510

















significant differences in TL parameters by 10 different
gene groups (Additional file 1: Table S4). Since TL var-
ies according to age in the normal population, the age
was compared between the mutational status of the
genes or gene groups. Significant differences were only
found for TET2 mutational status and the presence/
absence of mutation in DNA methylation genes cat-
egory. Patients with TET2 mutation and mutations of
DNA methylation were older than those without mu-
tation (P = 0.021, 0.008, respectively). The TL was not
significantly different between patients with or without
certain cytogenetic abnormalities by karyotyping or FISH
(Table 3). In summary, we found that the presence of any
gene mutation, but not the cytogenetic results, was related
to TL.
Survival analysis
The OS was compared among different clinical subgroups
(Fig. 5). There were significant differences in survival
among different IPSS and the revised IPSS risk groups
(P = 0.010, 0.004, respectively). However, no difference
in OS was observed among the WHO categories (P =
0.462) by Kaplan-Meier survival analysis.
Fig. 5 Kaplan-Meier survival curves according to WHO subtypes, IPSS subgroups, telomere lengths, and TP53 and U2AF1 mutation status
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The OS between those with or without certain gene
mutations was compared in genes with mutations that
were found in more than 5 % of the patients. We found
that patients with TP53 mutation and U2AF1 mutation
had a significantly shorter OS compared to those without
mutation (median survival 32.6 vs. 6.0 months, P < 0.001
for TP53 mutation, 32.6 vs. 15.5, P = 0.035 for U2AF1 mu-
tation). We also compared the OS of patients with ≥80
vs. <80 % of their cells with TL below the lowest 10th
percentile TL of normal controls, and the former was
significantly shorter (12.9 vs. 32.6 months, P = 0.017).
The OS was significantly different in patients with ≥80
vs. <80 % of their cells with TL below the lowest 10th
percentile TL of the NC even within WHO subtypes
and IPSS subgroups (P = 0.038, 0.022, respectively).
The presence of other mutations was not related to the
OS.
Patients with complex karyotype (P = 0.015), del(7q)/−7
by karyotype (P < 0.001), abnormalities of 17p by karyo-
type (P = 0.001), abnormalities on FISH for chromosome 5
and 7 (P = 0.014, P < 0.001, respectively), high BM blast
count (≥10 %) (P = 0.014), and those patients with ≥80 %
of TL under the 10th percentile of the NC (P = 0.021)
showed significantly lower survival than those without ab-
normalities. Univariable and multivariable Cox analyses
for overall survival were performed with the clinical pa-
rameters, mutational profiles and TL parameters (Table 4).
Excluding those parameters with significant correlation
and many missing values, multivariable Cox analysis
showed that the TP53 mutation, U2AF1 mutation, high
BM blast count (≥10 %), and high percentage (≥80 %)
of cells with TL less than the 10th percentile of the NC
were independent prognostic factors for survival in pa-
tients with MDS (Table 4). The Harrell’s C-index was
0.649 (0.579–0.719) for the revised IPSS only and 0.717
(0.654–0.779) for the model including TL, TP53, and
U2AF1 mutation and blast count showing similar pre-
diction power for survival in our model including TL.
Discussion
The findings of shortened TL in many MDS patients
have led to the studies of telomere dynamics [9, 11, 38, 39]
and its relationship with MDS [16]. The shortest TL in an
individual, which is considered to be critical in cellular sur-
vival and telomere dysfunction [21, 40] was measured by
Q-FISH in a single cell level in patients with MDS. We
have found out that in addition to the mean TL, the mini-
mum was also shorter in the MDS patients, and the pa-
tients showed a narrower range of TL than the NC. In
average, 52.2 % of each patient had a TL of lower than the
10th percentile of the NC, suggesting a high burden of cells
with critically short TL in the patients with MDS.
Few studies have analyzed the association of mutation
status; only that of the telomerase complex-related genes
and TL in MDS patients [17, 18]. Some patients with
telomere attrition had TERC or TERT mutations, but only
a small number of patients were included in each study
[17]. Therefore, we evaluated TL in relation to mutation
of myeloid neoplasia-related genes and genes commonly
found in hematologic malignancies. Patients without gene
mutations had shorter TL than those with mutation
(regardless of the gene), but comparing the TL between
those and those without each specific gene mutation,
the difference was only present for CSF3R gene. In the
present study, the population with TL below the 10th
percentile TL of the NC was markedly low in patients with
CSF3R mutation. It is well known that mutation of CSF3R
is accompanied in congenital neutropenia. The congenital
neutropenia patients that did not develop leukemia had an
incidence of CSF3R mutation in 34 %, compared to
Table 4 Univariable and multivariable Cox analysis of the overall survival of 58 MDS patients
Univariable Multivariable
Risk factors HR 95 % CI P HR 95 % CI P
Revised IPSS 0.010
Very low vs. low 2.242 0.275–18.287 0.451
Very low vs. intermediate 1.577 0.184–13.552 0.678
Very low vs. high 6.731 0.874–51.865 0.067
Very low vs. very high 6.432 0.808–51.197 0.079
Complex CG vs. not 2.915 1.229–6.918 0.015
del(7q)/−7 vs. normal (karyotype) 4.483 1.951–10.302 <0.001
FISH 5 abnormal vs. normal 2.994 1.248–7.183 0.014
BM blast ≥10 vs. <10 % 2.476 1.200–5.112 0.014 2.623 1.237–5.563 0.012
TP53 mutated vs. normal 4.875 2.031–11.703 <0.001 5.257 1.341–33.095 0.001
U2AF1 mutated vs. normal 2.325 1.035–5.222 0.041 3.544 1.485–8.458 0.004
Percentage of cells with low TL compared to NC ≥80 vs. <80 % 2.47 1.148–5.314 0.021 2.248 1.023 – 4.937 0.044
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78 % for patients who showed transformation into acute
leukemia [41]. Mutation of CSF3R could confer the
proliferative activity to the hematopoietic stem cell,
which possibly leads to a transformation to AML. This
may be reflected in the TL of patients with CSF3R, hav-
ing lesser portion of cells with short telomeres and one
of our patients showed AML transformation shortly
after diagnosis. The mutation site of CSF3R in MDS pa-
tients was different from the known site of mutation in
congenital neutropenia but two of the patients showed
CSF3R mutation reported in myeloid neoplasms such
as chronic neutrophilic leukemia or chronic myelomono-
cytic leukemia [42].
The hypothesis of this study was that TL erosion might
be more significant in certain groups of patients with gene
mutations that are known be correlated with telomere
dysfunction such as SRSF2 [16]. However, as TL is known
to be affected by many other factors including age, envir-
onment, gender, stress, oxidative stress, and emotion
[20, 43, 44], we were unable to show a correlation of
TL in relation to a single gene mutation except for
CSF3R. Contrary to our expectation, we found out that
regardless of the gene mutation type, those patients
with more than one gene mutation had higher TL than
those without mutation. This finding somewhat contrasts
with the recently reported result of aplastic anemia pa-
tients. Dumitriu et al. reported that telomere attrition and
somatic mutations precede monosomy 7 and that the ac-
cumulation of short telomere in each chromosome may
have a link to the development of aneuploidy in severe
aplastic anemia (AA) [45]. This explanation can be applied
to MDS evolved from previous AA. However, we infer
that telomere attrition in AA exert a different influence on
hematopoietic cells in case of MDS. AA has a decreased
hematopoietic stem cell pool, but MDS has a dysfunc-
tional hematopoietic stem cell pool, which has already ac-
quired oncogenic mutations. Although the patients with
gene mutations had longer TL than those without muta-
tion in this study, the TL was still shorter than those of
the NC. Comparisons within MDS groups may be less
useful than the comparison of TL within an individual
since telomere lengths are affected by many factors
[20, 43, 44] including therapy, which was shown in a
study that evaluated TL changes with treatment [46].
Another explanation may be that the mutations found
in these patients were in the genes related to splicing
machinery, DNA methylation, chromatin modification,
or cohesion complexes and they are known to be mu-
tated in MDS patients as driver/oncogenic mutations
[14]. Therefore, these oncogenic mutations may have
given the MDS cells the characteristics of “cancer” cells,
which maintain telomere lengths [47], thus showing lon-
ger TL in patients with gene mutation. On the other hand,
another explanation may be that these patients without
gene mutations may have incorporated a mechanism that
further shortens the length of the telomeres in this group.
Mutations in other genes not included in this study such
as TERC or TERT may give clue to these patients [17, 18].
Since no other study compared the TL of MDS patients
and the presence of genetic mutation commonly found in
hematologic malignancies, further studies would help elu-
cidate the relationship between the telomere length and
somatic mutations.
In addition, as TL is also regulated by the telomerase
activity (TA) [1], we believe that the TA results would
give additional information about the telomere dynam-
ics. However, due to the sample limitation, TA could not
be measured. TA was measured in MDS in few other
studies, and MDS showed normal to low levels of tel-
omerase activity [9, 48] despite the short TL. These re-
sults suggest the disruption of telomere maintenance in
patients with MDS and suggest the maintenance of TL
may be to some extent independent of TA incorporating
alternative lengthening of telomere mechanisms, as is
found in 10–15 % of the tumors [47].
The evaluation of TL with disease progression may be
more informative and some reported telomere attrition
during progression to acute myeloid leukemia [38, 49]
but were shown in a small number of patients, thus
requiring further study. In our study, there was no
correlation of TL with various clinical subgroups and
cytogenetic abnormalities, which is in line with previ-
ous studies showing inconsistent association between
clinical factors and TL [9, 12]. Our finding may partly
be due to the small number of patients included in
our study, which is a major limitation of this study.
Since cells with critically shortened telomeres may show
repeated fusion bridge cycles, which leads to accumulation
of chromosomal abnormalities, the relationship between
chromosomal aberrations [50] and TL were also assessed.
However, no significant change was found in relation to
those with or without chromosomal aberrations. In
addition to TP53 mutation, U2AF1 mutation was also
suggested to be associated with a poor risk [51, 52] and
was incorporated in the prognostic model along with
the blast count and having high percentage of cells
(≥80 %) with TL lower than the 10th percentile of the
NC. Although the shortest telomere, the minimum TL,
which is thought to be critical in the maintenance of
cell survival, did not show prognostic significance in
our study, we have found that having a high percentage
of cells with short TL compared to NC may be of prog-
nostic significance. The short TL was defined by having
shorter than the lower 10th percentile value of the NC
and this value may already suggest a portion of cells
with critically short telomeres. Despite the limitation
that Q-FISH measures the relative TL, the comparison
made with the NC allowed us to confirm the shortened
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TL in MDS. Measuring TL in individual cells by Q-FISH
also enabled us to identify the portion of cells with the
short telomeres, which is not obtainable when measured
by Southern blot or QPCR, which can only show the
average TL. Moreover, our model including the TL par-
ameter was comparable in the prediction of survival by
Harrell’s C-index suggesting a probability of incorpor-
ation of TL and somatic mutation as a useful marker
for prognostication.
Conclusions
In summary, we evaluated the telomere lengths of MDS
patients at a single-cell level by quantitative FISH
assessing the shortest TL in each individual along with
the average and distribution of TLs. Patients with mye-
lodysplastic syndrome showed short telomere lengths
compared to the control with a significant proportion of
cells having shorter telomeres than the 10th percentile of
the normal control. A proportion of cell population with
shorter TL below the 10th percentile of the normal con-
trol was significantly larger. We conclude that MDS is
characterized by concentrated hematopoietic cells with
short telomere, a kind of senescent cells. There were no
specific somatic mutation or cytogenetic aberration cor-
relating with short TL, but patients without somatic muta-
tion harbored short telomere than those with somatic
mutation. Interestingly, CSF3R mutation correlated with
longer telomere length, and proportion of short telomere
length was significantly small. TL parameter showed in-
dependent prognostic significance and incorporating
somatic mutation and TL in addition to known prog-
nostic markers may give additional prediction power
for prognosis.
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